InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-03-19 | John Boozman(R) | senate | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Sales to customers | $94.19B+6.0% | $88.82B+4.3% | $85.16B+6.5% | $79.99B+1.6% | $78.74B |
| Cost of products sold | $30.26B+10.1% | $27.47B+3.5% | $26.55B+8.0% | $24.60B+5.1% | $23.40B |
| Gross profit | $63.94B+4.2% | $61.35B+4.7% | $58.61B+5.8% | $55.39B+0.1% | $55.34B |
| Selling, marketing and administrative expenses | $23.68B+3.5% | $22.87B+6.3% | $21.51B+6.3% | $20.25B+0.6% | $20.12B |
| Research and development expense | $14.66B-14.9% | $17.23B+14.2% | $15.09B+6.7% | $14.13B-1.0% | $14.28B |
| In-process research and development impairments | $81.0M-61.6% | $211.0M-32.6% | $313.0M-60.0% | $783.0M-13.0% | $900.0M |
| Interest income | -$1.06B+20.7% | -$1.33B-5.6% | -$1.26B-157.3% | -$490.0M-824.5% | -$53.0M |
| Interest expense, net of portion capitalized | $971.0M+28.6% | $755.0M-2.2% | $772.0M+179.7% | $276.0M+50.8% | $183.0M |
| Other (income) expense, net | -$7.21B-253.6% | $4.69B-29.2% | $6.63B+719.0% | $810.0M+54.0% | $526.0M |
| Restructuring | $228.0M-2.6% | $234.0M-52.1% | $489.0M+77.8% | $275.0M+31.6% | $209.0M |
| Earnings before provision for taxes on income | $32.58B+95.2% | $16.69B+10.8% | $15.06B-22.2% | $19.36B+0.9% | $19.18B |
| Effective Rate | $5.78B+120.4% | $2.62B+51.0% | $1.74B | — | — |
| Net earnings from continuing operations | $26.80B+90.6% | $14.07B+5.6% | $13.33B-18.6% | $16.37B-8.0% | $17.80B |
| Net earnings from discontinued operations | $0 | $0-100.0% | $21.83B+1289.4% | $1.57B-48.9% | $3.08B |
| Net earnings | $26.80B+90.6% | $14.07B-60.0% | $35.15B+95.9% | $17.94B-14.1% | $20.88B |
| Basic net earnings per share from continuing operations (in dollars per share) | $11.1M+90.6% | $5.8M+11.0% | $5.3M-15.6% | $6.2M-7.8% | $6.8M |
| Basic net earnings per share from discontinued operations (in dollars per share) | $0 | $0-100.0% | $8.6M+1336.7% | $600K-48.7% | $1.2M |
| Basic (in dollars per share) | $11.1M+90.6% | $5.8M-57.9% | $13.9M+103.2% | $6.8M-13.9% | $7.9M |
| Diluted net earnings per share from continuing operations (in dollars per share) | $11.0M+90.5% | $5.8M+11.3% | $5.2M-15.3% | $6.1M-7.8% | $6.7M |
| Diluted net earnings per share from discontinuing operations (in dollars per share) | $0 | $0-100.0% | $8.5M+1344.1% | $590K-48.7% | $1.1M |
| Diluted (in dollars per share) | $11.0M+90.5% | $5.8M-57.8% | $13.7M+103.9% | $6.7M-13.8% | $7.8M |
| Basic (in shares) | $2.41B+0.0% | $2.41B-5.0% | $2.53B-3.5% | $2.63B-0.3% | $2.63B |
| Diluted (in shares) | $2.43B+0.0% | $2.43B-5.1% | $2.56B-3.9% | $2.66B-0.4% | $2.67B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Johnson & Johnson (JNJ) Highlights Sustained Efficacy in Vivacity-MG3 Trial
5 Dividend Increases Expected In May 2026
Microsoft says it has over 20M paid Copilot users, and they really are using it
AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock.
46% of Americans Split Their Investments Into Separate Buckets. Should Your Retirement Strategy Too?
ABBV Beats on Q1 Earnings & Sales, Raises '26 EPS View
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth
FDA Decisions Put Johnson & Johnson’s Growth And Valuation In Focus
‘American industry is winning’: White House touts factory boom — how investors can ride the reshoring wave
SBIO: Leaning Into Drug Discovery And Medical Breakthroughs
Best Dividend Aristocrats: April 2026
Recursion Pharmaceuticals May Be Losing Ground To Its Peers